These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36275783)

  • 1. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
    Bottiglieri A; Sepe P; Stellato M; Pircher C; Fotia G; Leone AG; Guadalupi V; Claps M; Giannatempo P; Verzoni E; Procopio G
    Cancer Manag Res; 2022; 14():3071-3081. PubMed ID: 36275783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
    Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
    Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
    Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
    Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2022 Feb; 81(2):134-137. PubMed ID: 34920897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
    Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
    Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.
    Karakiewicz PI; Zaffuto E; Kapoor A; Basappa NS; Bjarnason GA; Blais N; Breau RH; Canil C; Drachenberg D; Hotte SJ; Jeldres C; Jewett MAS; Kassouf W; Kollmannsberger C; Lavallée LT; Maloni R; Patenaude F; Pouliot F; Reaume MN; Sabbagh R; Shayegan B; So A; Soulières D; Tanguay S; Wood L; Bandini M
    Can Urol Assoc J; 2018 Jun; 12(6):173-180. PubMed ID: 29877179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab.
    Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
    Semin Oncol; 2022 Apr; 49(2):136-140. PubMed ID: 35610060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
    Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
    Zouein J; Naim N; Kourie HR
    Immunotherapy; 2023 Feb; 15(2):93-100. PubMed ID: 36601860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
    Serzan M; Atkins MB
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
    Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
    Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
    Cosso F; Roviello G; Nesi G; Shabani S; Spatafora P; Villari D; Catalano M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival.
    Ossato A; Gasperoni L; Del Bono L; Messori A; Damuzzo V
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.
    Massari F; Di Nunno V; Mollica V; Graham J; Gatto L; Heng D
    Clin Genitourin Cancer; 2019 Apr; 17(2):e339-e344. PubMed ID: 30704796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sonbol MB; Firwana B; Hilal T; Wang Z; Almader-Douglas D; Joseph RW; Ho TH
    Eur Urol Oncol; 2018 Jun; 1(2):101-108. PubMed ID: 30345423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.